ICU鲍氏不动杆菌耐药性分析

Drug resistance of Acinetobacter baumanniiin ICU

目的分析ICU鲍氏不动杆菌的耐药性,以指导临床合理用药。方法回顾性分析2011年上半年医院ICU临床分离的146株鲍氏不动杆菌的耐药率。结果 146株鲍氏不动杆菌主要来源于下呼吸道标本,占93.15%,除头孢哌酮/舒巴坦及米诺环素外,其他各种抗菌药物耐药率均>52.74%,头孢哌酮/舒巴坦的敏感率最高,为56.85%;多药耐药菌株检出率由2009年的44.4%上升至62.33%。结论 ICU鲍氏不动杆菌的耐药性及多药耐药菌的感染呈增长趋势,头孢哌酮/舒巴坦对鲍氏不动杆菌有较好的抗菌活性。

OBJECTIVE To analyze the drug resistance of the A. baumannii in ICU so as to guide the reasonable use of antibiotics. METHODS The drug resistance rates of 146 clinical isolates of A. baumannii isolated in the first half of 2011 were retrospectively analyzed. RESULTS Of the 146 strains of A. baumannii, the specimens of lower respiratory tract were the predominant source, accounting for 93.15 % the drug resistance rate was higher than 52.74% to all the antibiotics except cefoperazone/sulbactam and minocycline, and the drug susceptibility rate to cefoperazone/sulbactam was the highest （56.85%）; the isolation rate of the multidrug-resistant strains increased from 44.4% to 62. 33% in 2009. CONCLUSION The drug resistance of the A. baumannii and the incidence of multidrug-resistant bacteria infections in the ICU show an upward trend, and cefoperazone/sulbactam has good antibacterial activity against the A. baumannii.